A PHASE 1 TRIAL OF BTM-3566 IN RELAPSED/REFRACTORY MATURE B CELL LYMPHOMAS AND ADVANCED SOLID TUMORS
- Registry ID
- BTM-3566-001-CA
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- BANTAM PHARMACEUTICALS
- Start date
- 2025-10-20
- Last update
- 2024-11-12
Conditions
- ADVANCED SOLID TUMORS
- NON-HODGKIN LYMPHOMA
Related clinical trials
- A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MK-1045 MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH NON-HODGKIN LYMPHOMA
- A PHASE II, MULTI-CENTER, MASTER PROTOCOL TO EVALUATE THE EFFICACY AND SAFETY OF VOLRUSTOMIG AS MONOTHERAPY OR IN COMBINATION WITH ANTI-CANCER AGENTS IN PARTICIPANTS WITH ADVANCED/METASTATIC SOLID TUMORS
- A PHASE 1, OPEN-LABEL, MULTICENTER STUDY OF GSK5533524 ALONE OR IN COMBINATION WITH OTHER ANTI-CANCER AGENTS, IN ADULT PARTICIPANTS WITH SELECTED ADVANCED SOLID TUMORS
- A PHASE 1, 2-PART, MULTICENTER, OPEN-LABEL, FIRST-IN-HUMAN STUDY OF THE ANTI-LY6E EXATECAN ANTIBODY-DRUG CONJUGATE M7437 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
- A PHASE 1/2A, OPEN-LABEL, MULTICENTER STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PRELIMINARY EFFICACY OF BMS-986523 AS MONOTHERAPY AND IN COMBINATION WITH ANTI-CANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID MALIGNANCIES
- A PHASE 1 OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF NDI-219216 AS A SINGLE AGENT IN PATIENTS WITH ADVANCED SOLID TUMORS WITH AND WITHOUT MICROSATELLITE INSTABILITY AND/OR DEFICIENT MISMATCH REPAIR
View on source registry